NEUROBLASTOMA

This early-stage trial tests a new type of immunotherapy for children and young adults with solid tumors that have not responded to standard treatments. The therapy uses the patient's own immune cells (T cells) that are genetically modified to recognize and attack cancer cells ca…

This early-stage trial tests a new approach for children and young adults with neuroblastoma that has come back or not responded to standard treatments. Doctors take a patient's own immune cells (T-cells), genetically modify them in the lab to recognize and attack a protein calle…

This early-phase trial tests a new type of cell therapy for children and young adults with solid tumors that have come back or not responded to standard treatments. The therapy uses a patient's own immune cells, which are trained in the lab to recognize and attack multiple cancer…

This early-stage trial tests a combination of three drugs—sorafenib, cyclophosphamide, and topotecan—in children and young adults with neuroblastoma that has relapsed or not responded to treatment. The main goal is to find the highest safe dose of sorafenib when given with the tw…

This early-phase study tests a new treatment for advanced osteosarcoma and neuroblastoma that has not responded to standard therapy. Researchers take a patient's own immune cells (T cells), add a gene to help them recognize and attack cancer cells, and combine them with a chicken…

This early-phase study tests a flavored, drinkable version of the chemotherapy drug irinotecan (VAL-413) combined with another drug (temozolomide) in children and young adults up to age 30 whose solid tumors have come back. The main goal is to find the safest dose and see how the…

This study tests a tumor vaccine combined with daily low-dose chemotherapy for children whose high-risk neuroblastoma has returned or not responded to standard treatment. The vaccine is designed to train the immune system to recognize and attack neuroblastoma cells, while the low…

This early-stage trial tests a radioactive drug called CLR 131 in 30 children and young adults with solid tumors, lymphoma, or brain tumors that have come back or not responded to standard treatments. The main goals are to find a safe dose and see if the drug can shrink tumors. P…

This trial tests a bivalent vaccine designed to help the immune system recognize and attack neuroblastoma cells. The vaccine contains two antigens (GD2L and GD3L) found on neuroblastoma cells, plus an adjuvant (OPT-821) to boost the immune response. Participants also take oral β-…

This study tests whether adding two chemotherapy drugs (irinotecan and temozolomide) to the standard immunotherapy regimen (dinutuximab, GM-CSF, isotretinoin) can safely prevent high-risk neuroblastoma from returning after intensive initial therapy. About 41 children and young ad…

This study tests an oral drug called DFMO in children and young adults with high-risk neuroblastoma who are currently in remission. The goal is to see if taking DFMO for two years can prevent the cancer from coming back. The trial involves 441 participants and focuses on safety a…

This study tested whether a fecal transplant (transferring healthy gut bacteria from a donor) could help treat neuroblastoma, a rare childhood cancer. The approach aimed to fix gut bacteria imbalances before and during standard cancer treatment. Only one patient was enrolled, and…

This early-stage trial tests a new treatment called GD2 CAR T cells in 12 children and teens (ages 1-16) with neuroblastoma that has come back or not responded to standard therapy. The treatment involves taking a patient's own immune cells, modifying them to better recognize and …

This study tests a combination of two drugs—an antibody called Hu3F8 and a growth factor called GM-CSF—in children with high-risk neuroblastoma that has come back or not responded to standard therapy. The goal is to find the safest dose and understand side effects. About 186 part…

This early-stage study tests a new drug called LY3295668 erbumine in people with neuroblastoma that has returned or not responded to standard therapy. The main goal is to check safety and find the right dose. About 71 participants will receive the drug alone or with other medicin…

This early-phase trial tests a treatment that uses a child's own natural killer (NK) cells, boosted in the lab, along with standard antibody therapy (dinutuximab) for relapsed or hard-to-treat neuroblastoma. The study aims to find the safest dose of NK cells and see if adding len…

This study tests a personalized approach for children with non-high-risk neuroblastoma, where treatment is guided by the tumor's biology and how it responds over time. Some children may only need monitoring instead of immediate therapy, potentially avoiding harsh side effects. Th…

This early-stage study tests a combination of three drugs (radioactive therapy, an immunotherapy, and a checkpoint inhibitor) in children whose neuroblastoma has returned or not responded to standard treatment. The main goal is to see if the combination is safe and tolerable. Abo…

This early-phase study tests a personalized cell therapy for children and young adults (up to age 26) with solid tumors that have come back or not responded to standard treatment. The therapy uses the patient's own immune cells, modified to recognize and attack a protein called B…

This early-stage trial tests a personalized treatment for children with recurrent neuroblastoma or a rare brainstem tumor called DIPG. The approach combines targeted drugs with the child's own immune cells, trained to attack the cancer. The main goal is to check safety and find t…

This early-phase study tests a new gene therapy for children whose neuroblastoma has returned or not responded to treatment. Researchers take the patient's own immune cells, add genes to help them recognize and attack the cancer, and give them back along with chemotherapy and an …

This study tests whether a special PET scan using a radioactive form of methionine (a natural amino acid) can help doctors see tumors in children and young adults with various cancers, including brain tumors and sarcomas. About 503 participants will be scanned to see if the metho…

This study tests a new radioactive imaging agent, 18F-mFBG, used with PET scans to find neuroblastoma in children and adults. About 43 participants with known or suspected neuroblastoma will receive the agent and have a PET scan. The goal is to see if this method accurately confi…

This study tests whether a new type of PET/CT scan, using a radioactive tracer called 68Ga-DOTATOC, can find neuroendocrine tumors (NETs) and similar tumors more safely and accurately than current imaging methods. About 800 people with known or suspected NETs will receive the sca…

This study tests a new radioactive tracer called 18F-DA for PET scans to see if it can find neuroblastoma and pheochromocytoma tumors more clearly than the current tracer. About 20 children and adults with known or suspected tumors will receive the tracer and be monitored for sid…

This study involves 20 children and young adults with neuroendocrine tumors (like neuroblastoma) that have spread. Researchers are testing whether a special PET/CT scan using a radioactive tracer called 68Ga-DOTATATE can find tumors better than the standard MIBG scan. The goal is…

This study tests if giving the drug dinutuximab over 4 hours or less is safe and practical for children with high-risk neuroblastoma. Currently, standard infusions take 10-20 hours and require a hospital stay. The goal is to see if a shorter infusion can be used in an outpatient …

This study searches for new gene changes (mutations) that appear in cancer patients but not in their healthy parents. By comparing DNA from 1,275 people with certain cancers and their families, researchers hope to find genetic clues that increase cancer risk. The goal is to bette…

This study uses a radioactive antibody called Hu3F8 to take detailed PET/CT pictures of tumors in people with melanoma, neuroblastoma, or sarcoma. The goal is to see how the antibody moves through the body and where it collects. Seven participants received the antibody and had mu…

This study looks at tumor samples from children and young adults (ages 1 to 30) with high-risk neuroblastoma that has come back or not responded to treatment. The goal is to find specific genetic changes and immune system markers that could guide future treatments. No new therapy…

This study tests a new, highly detailed PET/CT scanner (NeuroEXPLORER) against the standard scanner for people with conditions like dementia, Parkinson's, brain tumors, and head/neck cancers. About 1600 participants will get both scans in one visit to see if the new scanner gives…